Novem Group Has $1.43 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Novem Group raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 27.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,407 shares of the biopharmaceutical company's stock after acquiring an additional 4,821 shares during the quarter. Novem Group's holdings in Halozyme Therapeutics were worth $1,430,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Halozyme Therapeutics by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after purchasing an additional 386,618 shares in the last quarter. Snyder Capital Management L P raised its stake in Halozyme Therapeutics by 2.6% during the fourth quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company's stock valued at $199,294,000 after buying an additional 105,086 shares in the last quarter. Congress Asset Management Co. lifted its holdings in Halozyme Therapeutics by 8.8% during the 1st quarter. Congress Asset Management Co. now owns 2,132,707 shares of the biopharmaceutical company's stock worth $136,088,000 after buying an additional 172,971 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Halozyme Therapeutics by 2.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company's stock worth $92,446,000 after buying an additional 47,795 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of Halozyme Therapeutics by 8.7% in the 4th quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company's stock worth $87,386,000 after acquiring an additional 145,617 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 4,497 shares of Halozyme Therapeutics stock in a transaction on Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the transaction, the director directly owned 28,611 shares in the company, valued at approximately $1,727,246.07. This trade represents a 13.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $53.73, for a total value of $1,074,600.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares in the company, valued at $39,422,721.87. This represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 44,497 shares of company stock worth $2,405,284. Company insiders own 2.40% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on HALO shares. Benchmark lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Wells Fargo & Company increased their target price on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Leerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Morgan Stanley downgraded shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $73.00 to $62.00 in a research report on Wednesday, May 14th. Finally, JPMorgan Chase & Co. raised their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $61.90.

Halozyme Therapeutics Stock Performance

NASDAQ HALO traded up $0.21 on Friday, hitting $54.05. The stock had a trading volume of 868,065 shares, compared to its average volume of 1,756,229. The company's 50-day moving average is $55.49 and its two-hundred day moving average is $56.64. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $70.51. The stock has a market cap of $6.66 billion, a price-to-earnings ratio of 12.74, a P/E/G ratio of 0.36 and a beta of 1.15. The company has a quick ratio of 7.30, a current ratio of 8.39 and a debt-to-equity ratio of 3.13.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, beating the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The firm had revenue of $264.86 million for the quarter, compared to analysts' expectations of $231.21 million. During the same period last year, the firm earned $0.79 EPS. The firm's revenue was up 35.2% compared to the same quarter last year. On average, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.